Top

Current Diabetes Reports

Published in:

01-10-2018 | Microvascular Complications—Neuropathy (R Pop-Busui, Section Editor)

The Potential Role of Fatty Acids in Treating Diabetic Neuropathy

Author: Mark A. Yorek

Published in: Current Diabetes Reports | Issue 10/2018

Abstract

Purpose of review

This review will summarize recent findings of the effect of supplemental fatty acids, with an emphasis on omega-3 polyunsaturated fatty acids, as a treatment for diabetic peripheral neuropathy.

Recent findings

Pre-clinical studies have provided evidence that treating diabetic rodents with δ linolenic acid (omega-6 18:3) and to a greater extent with eicosapentaenoic and docosahexaenoic acids (omega-3 20:5 and 22:6, respectively) improve and even reverse vascular and neural deficits. Additional studies have shown resolvins, metabolites of eicosapentaenoic and docosahexaenoic acids, can induce neurite outgrowth in neuron cultures and that treating type 1 or type 2 diabetic mice with resolvin D1 or E1 provides benefit for peripheral neuropathy similar to fish oil.

Summary

Omega-3 polyunsaturated fatty acids derived from fish oil and their derivatives have anti-inflammatory properties and could provide benefit for diabetic peripheral neuropathy. However, clinical trials are needed to determine whether this statement is true.

•• Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:136–54. https://doi.org/10.2337/dc16-2042. This article includes the position statement from the ADA relating to peripheral neuropathy. CrossRefPubMed

•• Grisold A, Callaghan BC, Feldman EL. Mediators of diabetic neuropathy: is hyperglycemia the only culprit? Curr Opin Endocrinol Diabetes Obes. 2017;24:103–11. https://doi.org/10.1097/MED.0000000000000320. This review article describes how metabolic dysregulation as well as non-metabolic factors can contribute to diabetic neuropathy. CrossRefPubMedPubMedCentral

•• Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther. 2018;40:828–49. https://doi.org/10.1016/j.clinthera.2018.04.001. This review utilized a comprehensive literature search and provides background on the epidemiology; diagnosis, and the treatment of neuropathic pain in diabetic peripheral neuropathy. CrossRefPubMed

Shin JY, Roh SG, Sharaf B, Lee NH. Risk of major limb amputation in diabetic foot ulcer and accompanying disease: a meta-analysis. J Plast Reconstr Aesthet Surg. 2017;70:1681–8. https://doi.org/10.1016/j.bjps.2017.07.015.CrossRefPubMed

Narres M, Kvitkina T, Claessen H, Droste S, Schuster B, Morbach S, et al. Incidence of lower extremity amputations in the diabetic compared with the non-diabetic population: a systematic review. PLoS One. 2017;12:e0182081. https://doi.org/10.1371/journal.pone.0182081.CrossRefPubMedPubMedCentral

Papanas N, Ziegler D. Emerging drugs for diabetic peripheral neuropathy and neuropathic pain. Expert Opin Emerg Drugs. 2016;21:393–407. https://doi.org/10.1080/14728214.2016.1257605.CrossRefPubMed

Dy SM, Bennett WL, Sharma R, Zhang A, Waldfogel JM, Nesbit SA, et al. Preventing complications and treating symptoms of diabetic peripheral neuropathy. AHRQ Comparative Effectiveness Reviews Agency for Healthcare and Quality (US); 2017 March Report No:17-EHCOO5-EF.

Snyder MJ, Gibbs LM, Lindsay TJ. Treating painful diabetic peripheral neuropathy: a update. Am Fam Physician. 2016;94:227–34.PubMed

Dobrowsky RT. Targeting the diabetic chaperome to improve peripheral neuropathy. Curr Diab Rep. 2016;16:71. https://doi.org/10.1007/s11892-016-0769-8.CrossRefPubMedPubMedCentral

10.

• Pop-Busui R, Ang L, Holmes C, Gallagher K, Feldman EL. Inflammation as a therapeutic target for diabetic neuropathy. Curr Diab Rep. 2016;16:29. https://doi.org/10.1007/s11892-016-0727-5. This is a recent review article describing inflammation as a target for diabetic neuropathy. The article includes how different pathogenic mechanisms thought to contribute to diabetic neuropathy increase inflammatory stress. CrossRefPubMedPubMedCentral

11.

Rochette L, Ghibu S, Muresan A, Vergely C. Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Can J Physiol Pharmacol. 2015;93:1021–7. https://doi.org/10.1139/cjpp-2014-0353.CrossRefPubMed

12.

•• Fernyhough P. Mitochondrial dysfunction in diabetic neuropathy: a series of unfortunate metabolic events. Curr Diab Rep. 2015;15:89. https://doi.org/10.1007/s11892-015-0671-9. This was one of the earliest review article describing possible mechanisms responsible for mitochondrial dysfunction in diabetes. CrossRefPubMed

13.

Zhou J, Zhou S. Inflammation: therapeutic targets for diabetic neuropathy. Mol Neurobiol. 2014;49:536–46. https://doi.org/10.1007/s12035-013-8537-0.CrossRefPubMed

14.

Hosseini A, Abdollahi M. Diabetic neuropathy and oxidative stress: therapeutic perspectives. Oxidative Med Cell Longev. 2013;2013:168039–15. https://doi.org/10.1155/2013/168039.CrossRef

15.

Varkonyi T, Putz Z, Keresztes K, Martos T, Lengyel C, Stirban A, et al. Current options and perspectives in the treatment of diabetic neuropathy. Curr Pharm Des. 2013;19:4981–5007.CrossRefPubMed

16.

Stavniichuk R, Shevalye H, Lupachyk S, Obrosov A, Groves JT, Obrosova IG, et al. Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2014;30:669–78. https://doi.org/10.1002/dmrr.2549.CrossRefPubMedPubMedCentral

17.

Lupachyk S, Watcho P, Shevalye H, Vareniuk I, Obrosov A, Obrosova IG, et al. Na+/H+ exchanger 1 inhibition reverses manifestation of peripheral neuropathy in type 1 diabetic rats. Am J Physiol Endocrinol Metab. 2013;305:E396–404. https://doi.org/10.1152/ajpendo.00186.2013.CrossRefPubMedPubMedCentral

18.

Lupachyk S, Watcho P, Stavniichuk R, Shevalye H, Obrosova IG. Endoplasmic reticulum stress plays a key role in the pathogenesis of diabetic peripheral neuropathy. Diabetes. 2013;62:944–52. https://doi.org/10.2337/db12-0716.CrossRefPubMedPubMedCentral

19.

Obrosova IG, Drel VR, Oltman CL, Mashtalir N, Tibrewala J, Groves JT, et al. Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. Am J Physiol Endocrinol Metab. 2007;293:E1645–55. https://doi.org/10.1152/ajpendo.00479.2007.CrossRefPubMed

20.

Malik RA. Why are there no good treatments for diabetic neuropathy? Lancet Diabetes Endocrinol. 2014;2:607–9. https://doi.org/10.1016/S2213-8587(14)70067-1.CrossRefPubMed

21.

•• Malik RA. Wherefore art thou, O treatment for diabetic neuropathy? Int Rev Neurobiol. 2016;127:287–317. https://doi.org/10.1016/bs.irn.2016.03.008. This papers outlines some of the failures and issues associated with the lack of success in finding a treatment for diabetic neuropathy. CrossRefPubMed

22.

Holmes A, Coppey LJ, Davidson EP, Yorek MA. Rat models of diet-induced obesity and high fat/low dose streptozotocin type 2 diabetes: effect of reversal of high fat diet compared to treatment with enalapril or menhaden oil on glucose utilization and neuropathic endpoints. J Diabetes Res. 2015;307285:1–8. https://doi.org/10.1155/2015/307285.CrossRef

23.

Yorek MS, Obrosov A, Shevalye H, Holmes A, Harper MM, Kardon RH, et al. Effect of diet-induced obesity or type 1 or type 2 diabetes on corneal nerves and peripheral neuropathy in C57Bl/6J mice. J Peripher Nerv Syst. 2015;20:24–31. https://doi.org/10.1111/jns.12111.CrossRefPubMedPubMedCentral

24.

Davidson EP, Coppey LJ, Kardon RH, Yorek MA. Differences and similarities in development of corneal nerve damage and peripheral neuropathy and in diet-induced obesity and type 2 diabetic rats. Invest Ophthalmol Vis Sci. 2014;55:1222–30. https://doi.org/10.1167/iovs.13-13794.CrossRefPubMedPubMedCentral

25.

Davidson EP, Coppey LJ, Dake B, Yorek MA. Effect of treatment of Sprague-Dawley rats with AVE7688, enalapril, or candoxatril on diet-induced obesity. J Obes. 2011;686952:1–9. https://doi.org/10.1155/2011/686952.CrossRef

26.

Davidson EP, Coppey LJ, Calcutt NA, Oltman CL, Yorek MA. Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction. Diabetes Metab Res Rev. 2010;26:306–18. https://doi.org/10.1002/dmrr.1088.CrossRefPubMedPubMedCentral

27.

Obrosova IG, Ilnytska O, Lyzogubov VV, Pavlov IA, Mashtalir N, Nadler JL, et al. High-fat diet induced neuropathy of pre-diabetes and obesity: effects of “healthy” diet and aldose reductase inhibition. Diabetes. 2007;56:2598–608. https://doi.org/10.2337/db06-1176.CrossRefPubMed

28.

Hinder LM, O’Brien PD, Hayes JM, Backus C, Solway AP, Sims-Robinson C, et al. Dietary reversal of neuropathy in a murine model of prediabetes and metabolic syndrome. Dis Model Mech. 2017;10:717–25. https://doi.org/10.1242/dmm.028530.CrossRefPubMedPubMedCentral

29.

Xu L, Tang D, Guan M, Xie C, Xue Y. Effect of high-fat diet on peripheral neuropathy in C57Bl/6 mice. Int J Endocrinol 2014::305205. Doi:https://doi.org/10.1155/2014/305205.

30.

Ozay R, Uzar E, Aktas A, Uyar ME, Gurer B, Evliyaoglu O, et al. The role of oxidative stress and inflammatory response in high-fat diet induced peripheral neuropathy. J Chem Neuroanat. 2014;55:51–7. https://doi.org/10.1016/j.jchemneu.2013.12.003.CrossRefPubMed

31.

• Cortez M, Singleton JR, Smith AG. Glucose intolerance, metabolic syndrome, and neuropathy. Handb Clin Neurol. 2014;126:109–22. https://doi.org/10.1016/B978-0-444-53480-4. This paper presents studies demonstrating that peripheral neuropathy develops in human subjects in the pre-diabetic phase. CrossRefPubMed

32.

Papanas N, Ziegler D. Prediabetic neuropathy: does it exist? Curr Diab Rep. 2012;12:376–83. https://doi.org/10.1007/s11892-012-0278-3.CrossRefPubMed

33.

Cho YR, Lim JH, Kim MY, Kim TW, Hong BY, Kim YS, et al. Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice. PLoS One. 2014;9:e83204. https://doi.org/10.1371/journal.pone.0083204.CrossRefPubMedPubMedCentral

34.

Othman A, Benghozi R, Alecu I, Wei Y, Niesor E, von Eckardstein A, et al. Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: a novel approach for treating diabetic neuropathy? J Clin Lipidol. 2015;9:568–75. https://doi.org/10.1016/j.jacj.2015.03.011.CrossRefPubMed

35.

Czupryniak L, Joshi SR, Gogtay JA, Lopez M. Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review. Expert Opin Pharmacother. 2016;17:1463–73. https://doi.org/10.1080/14656566.2016.1195811.CrossRefPubMed

36.

Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Freemantle Diabetes Study. Diabetologia. 2008;51:562–6. https://doi.org/10.1007/s00125-007-0909-2.CrossRefPubMed

37.

Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009;373:1780–8. https://doi.org/10.1016/S0140-6736(09)60698-X.CrossRefPubMedPubMedCentral

38.

ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–44. https://doi.org/10.1056/NEJMoa1001288.CrossRef

39.

Grisold A, Callaghan BC, Feldman EL. Mediators of diabetic neuropathy: is hyperglycemia the only culprit? Curr Opin Endocrinol Diabetes Obes. 2017;24:103–11. https://doi.org/10.1097/MED.0000000000000320.CrossRefPubMedPubMedCentral

40.

Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:341–50.CrossRefPubMed

41.

Pitel S, Raccah D, Gerbi A, Pieroni G, Vague P, Coste TC. At low doses, a gamma-linolenic acid-lipoic acid conjugate is more effective than docosahexaenoic acid-enriched phospholipids in preventing neuropathy in diabetic rats. J Nutr. 2007;137:368–72. https://doi.org/10.1093/jn/137.2.368.CrossRefPubMed

42.

Brenner RR. Hormonal modulation of delta6 and delta5 desaturases: case of diabetes. Prostaglandins Leukot Essent Fatty Acids. 2003;68:151–62.CrossRefPubMed

43.

Tao M, McDowell MA, Saydah SH, Eberhardt MS. Relationship of polyunsaturated fatty acid intake to peripheral neuropathy among adults with diabetes in the National Health and Nutrition Examination Survey (NHANES) 1999–2004. Diabetes Care. 2008;31:93–5. https://doi.org/10.2337/dc07-0931.CrossRefPubMed

44.

Tomlinson DR, Robinson JP, Compton AM, Keen P. Essential fatty acid treatment: effects on nerve conduction, polyol pathway and axonal transport in streptozotocin diabetic rats. Diabetologia. 1989;32:655–9.CrossRefPubMed

45.

Cameron NE, Cotter MA, Robertson S. Essential fatty acid diet supplementation. Effects on peripheral nerve and skeletal muscle function and capillarization in streptozotocin-induced diabetic rats. Diabetes. 1991;40:532–9.CrossRefPubMed

46.

Burnard SL, McMurchie EJ, Leifert WR, Patten GS, Muggli R, Raederstorff D, et al. Cilazapril and dietary gamma-linolenic acid prevent the deficit in sciatic nerve conduction velocity in the streptozotocin diabetic rat. J Diabetes Complicat. 1998;12:65–73.CrossRef

47.

Coste T, Pierlovisi M, Leonardi J, Dufayet D, Gerbi A, Lafont H, et al. Beneficial effects of gamma linolenic acid supplementation on nerve conduction velocity, Na+, K+ ATPase activity, and membrane fatty acid composition in sciatic nerve of diabetic rats. J Nutr Biochem. 1999;10:411–20.CrossRefPubMed

48.

Cameron NE, Cotter MA, Horrobin DH, Trischler HJ. Effects of alpha-lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids. Diabetologia. 1998;41:390–9.CrossRefPubMed

49.

Hounsom L, Horrobin DF, Trischler H, Corder R, Tomlinson DR. A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia. 1998;41:839–43. https://doi.org/10.1007/s001250050996.CrossRefPubMed

50.

Shotton HR, Broadbent S, Lincoln J. Prevention and partial reversal of diabetes-induced changes in enteric nerves of the rat ileum by combined treatment with alpha-lipoic acid and evening primrose oil. Auton Neurosci. 2004;111:57–65. https://doi.org/10.1016/j.autneu.2004.02.004.CrossRefPubMed

51.

Ford I, Cotter MA, Cameron NE, Greaves M. The effects of treatment with alpha-lipoic acid or evening primrose oil on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat. Metabolism. 2001;50:868–75. https://doi.org/10.1053/meta.2001.24914.CrossRefPubMed

52.

Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabet Med. 1990;7:319–23.CrossRefPubMed

53.

Keen H, Payan J, Allawi J, Walker J, Jamal GA, Weir AI, et al. Treatment of diabetic neuropathy with gamma-linolenic acid. The Gamma-Linolenic Acid Multicenter Trial Group. Diabetes Care. 1993;16:8–15.CrossRefPubMed

54.

Palacios-Palaez R, Lukiw W, Bazan N. Omega-3 essential fatty acids modulate initiation and progression of neurodegenerative diseases. Mol Neurobiol. 2010;41:367–74. https://doi.org/10.1007/s12035-010-8139-z.CrossRef

55.

Farooqui A. n-3 fatty acid-derived lipid mediators in the brain: new weapons against oxidative stress and inflammation. Curr Med Chem. 2012;19:532–43.CrossRefPubMed

56.

Coppey L, Holmes A, Davidson E, Yorek M. Partial replacement with menhaden oil improves peripheral neuropathy in high-fat-fed low-dose streptozotocin type 2 diabetic rat. J Nutr Metab 2012:950517. https://doi.org/10.1155/2012/950517.CrossRef

57.

Coppey L, Davidson E, Obrosov A, Yorek M. Enriching the diet with menhaden oil improves peripheral neuropathy in streptozotocin-induced type 1 diabetic rats. J Neurophysiol. 2015;113:701–8. https://doi.org/10.1152/jn.00718.2014.CrossRefPubMed

58.

Shevalye H, Yorek M, Coppey L, Holmes A, Harper MM, Kardon RH, et al. Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes. J Neurophysiol. 2015;114:199–208. https://doi.org/10.1152/jn.00224.2015.CrossRefPubMedPubMedCentral

59.

Davidson E, Holmes A, Coppey L, Yorek M. Effect of combination therapy consisting of enalapril, α-lipoic acid, and menhaden oil on diabetic neuropathy in a high fat/low dose streptozotocin treated rat. Eur J Pharmacol. 2015;765:258–67. https://doi.org/10.1016/j.ejphar.2015.08.015.CrossRefPubMed

60.

•• Yorek M, Coppey L, Shevalye H, Obrosov A, Kardon R, Yorek M. Effect of treatment with salsalate, menhaden oil, combination of salsalate and menhaden oil, or resolvin D1 of C57Bl/6J type 1 diabetic mouse on neuropathic endpoints. J Nutr Metab 2016:5905891. https://doi.org/10.1016/j.ejphar.2015.08.015. One of the first papers demonstrating that salsalate when in combination with fish oil increases resolvin production greater than fish oil alone. CrossRefPubMed

61.

Yorek MS, Obrosov A, Shevalye H, Coppey LJ, Kardon RH, Yorek MA. Early vs. late intervention of high fat/low dose streptozotocin treated C57Bl/6J mice with enalapril, α-lipoic acid, menhaden oil or their combination: Effect on diabetic neuropathy related endpoints. Neuropharmacology. 2017;116:122–31. https://doi.org/10.1016/j.neuropharm.2016.12.022.CrossRefPubMed

62.

Spector AA, Yorek MA. Membrane lipid composition and cellular function. J Lipid Res. 1985;26:1015–35.PubMed

63.

Yorek MA. Is fish oil a potential treatment for diabetic peripheral neuropathy? Curr Diabetes Rev. 2017; https://doi.org/10.2174/1573399813666170522155327.CrossRefPubMed

64.

Roman-Pintos LM, Villegas-Rivera G, Rodriguez-Carrizalez AD, Miranda-Diaz AG, Cardona-Munoz EG. Diabetic polyneuropathy in type 2 diabetes mellitus: inflammation, oxidative stress, and mitochondrial function. J Diabetes Res. 2016;3425617:1–16. https://doi.org/10.1155/2016/3425617.CrossRef

65.

Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014;14:473. https://doi.org/10.1007/s11910-014-0473-5.CrossRefPubMedPubMedCentral

66.

Gerbi A, Maixent J, Ansaldi J, Pierlovisi M, Coste T, Pelissier JF, et al. Fish oil supplementation prevents diabetes-induec nerve conduction velocity and neuroanatomical changes in rats. J Nutr. 1999;129:207–13. https://doi.org/10.1093/jn/129.1.207.CrossRefPubMed

67.

Julu PO. Essential fatty acids prevent slowed nerve conduction in streptozotocin diabetic rats. J Diabet Complications. 1998;2:185–8.CrossRef

68.

Heng L, Qi R, Yang R, Xu G. Docosahexaenoic acid inhibits mechanical allodynia and thermal hyperalgesia in diabetic rats by decreasing the excitability of DRG neurons. Exp Neurol. 2015;271:291–300. https://doi.org/10.1016/j.expneurol.2015.06.022.CrossRefPubMed

69.

Li M, Wang Y, Cao R, Hou XH, Zhang L, Yang RH, et al. Dietary fish oil inhibits mechanical allodynia and thermal hyperalgesia in diabetic rats by blocking nuclear factor-κB-mediated inflammatory pathways. J Nutr Biochem. 2015;26:1147–55. https://doi.org/10.j.jnutbio.2015.05.005.

70.

Okuda Y, Mizutani M, Ogawa M, Sone H, Asano M, Asakura Y, et al. Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus. J Diabetes Complicat. 1996;10:280–7.CrossRef

71.

•• Lewis EJH, Perkins BA, Lovblom LE, Bazinet RP, Wolever TMS, Bril V. Effect of omega-3 supplementation on neuropathy in type 1 diabetes: a 12-month pilot trial. Neurology. 2017;88:2294–301. https://doi.org/10.1212/WNL.0000000000004033. First paper to demonstrate that treating diabetic patients with a source of omega-3 polyunsaturated fatty acids promotes corneal nerve regeneration. CrossRefPubMedPubMedCentral

72.

Pritchad N, Edwards K, Shahidi AM, Sampson GP, Russel AW, Malik RA, et al. Corneal markers of diabetic neuropathy. Ocul Surf. 2011;9:17–28.CrossRef

73.

Travakoli M, Quattrini C, Abbott C, Kallinikos P, Marshall A, Finnigan J, et al. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care. 2010;33:1792–7. https://doi.org/10.2337/dc10-0253.CrossRef

74.

Malik RA. Early detection of nerve damage and repair in diabetic neuropathy. Nat Clin Pract Neurol. 2008;4:646–7. https://doi.org/10.1038/ncpneuro0938.CrossRefPubMed

75.

Ariel A, Serhan C. Resolvins and protectins in the termination program of acute inflammation. Trends Immunol. 2007;28:176–83.CrossRefPubMed

76.

Kohli P, Levy B. Resolvins and protectins: mediating solutions to inflammation. Brit J Pharmacol. 2009;158:960–71. https://doi.org/10.1111/j.1476-5381.2009.00290.x.CrossRef

77.

Cortina M, He J, Li N, Bazan N, Bazan H. Neuroprotectin D1 synthesis and corneal nerve regeneration after experimental surgery and treatment with PEDF plus DHA. Invest Ophthalmol Vis Sci. 2010;51:804–10. https://doi.org/10.1167/iovs.09-3641.CrossRefPubMedPubMedCentral

78.

Gordon W, Bazan N. Mediator lipidomics in ophthalmology: targets for modulation in inflammation, neuroprotection and nerve regeneration. Curr Eye Res. 2013;38:995–1005. https://doi.org/10.3109/02713683.2013.827211.CrossRefPubMed

79.

Robson L, Dyall S, Sidloff D, Michael-Titus A. Omega-3 polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurons throughout development and in aged animals. Neurobiol Aging. 2010;31:678–87. https://doi.org/10.1016/j.neurobiolaging.2008.05.027.CrossRefPubMed

80.

• Obrosov A, Coppey LJ, Shevalye H, Yorek MA. Effect of fish oil vs. resolvin D1, E1, methyl esters of resolvins D1 or D2 on diabetic peripheral neuropathy. J Neurol Neurophysiol 2017:8: in press. Doi:https://doi.org/10.4172/2155-9562.1000453. The first paper to describe the effects of resolvin D1 and E1 on diabetic peripheral neuropathy.

81.

•• Yorek MA. Is fish oil a potential treatment for diabetic peripheral neuropathy? Curr Diabetes Rev 2017 in press. Doi:https://doi.org/10.2174/1573399813666170522155327. A recent review article describing the potential benefits of fish oil on diabetic neuropathy. CrossRefPubMed

82.

Coppey LJ, Shevalye H, Obrosov A, Davidson EP, Yorek MA. Determination of peripheral neuropathy in high-fat diet fed low-dose streptozotocin-treated female C57Bl/6J mice and Sprague-Dawley rats. J Diabetes Investig. 2018; https://doi.org/10.1111/jdi.12814.CrossRefPubMedPubMedCentral

83.

Chen J, Shetty S, Zhang P, Gao R, Hu Y, Wang S, et al. Aspirin-triggered resolvin D1 down-regulates inflammatory responses and protects against endotoxin-induced acute kidney injury. Tox Appl Pharma. 2014;277:118–23. https://doi.org/10.1016/j.taap.2014.03.017.CrossRef

84.

van Dam AD, Nahon KJ, Kooijman S, van den Berg SM, Kanhai AA, Kikuchi T, et al. Salsalate activates brown adipose tissue in mice. Diabetes. 2015;64:1544–54. https://doi.org/10.2337/db14-1125.CrossRefPubMed

85.

Chai W, Liu J, Fowler D, Barrett E, Liu Z. Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans. Diabetes Care. 2011;34:1634–8. https://doi.org/10.2337/dc10-2345.CrossRefPubMedPubMedCentral

86.

Ariel D, Kim SH, Liu A, Abbasi F, Lamendola CA, Grove K, et al. Salsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in overweight or obese, insulin-resistant, nondiabetic individuals. J Clinical Lipidol. 2015;9:658–63. https://doi.org/10.1016/j.jacl.2015.06.009.CrossRef

87.

Goldfine A, Fonseca V, Jablonski K, Pyle L, Staten M, Shoelson S. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010;152:346–57. https://doi.org/10.7326/0003-4819-152-6-201003160-00004.CrossRefPubMedPubMedCentral

88.

Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, et al. Salicylate (salsalate) in patients with type 2 diabetes. Ann Intern Med. 2013;159:1–12. https://doi.org/10.7326/0003-4819-159-1-201307020-00003.CrossRefPubMedPubMedCentral

89.

Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008;1:36–43. https://doi.org/10.1111/j.1752-8062.2008.00026.x.CrossRefPubMedPubMedCentral

90.

Davidson EP, Coppey LJ, Shevalye H, Obrosov A, Yorek MA. Effect of dietary content of menhaden oil with or without salsalate on neuropathic endpoints in high fat fed/low dose streptozotocin treated Sprague-Dawley rats. J Diabetes Res. 2018;2969127. https://doi.org/10.1155/2018/2967127.CrossRef

91.

Mantovani A, Rigolon R, Mingolla L, Pichiri I, Cavalieri V, Salvotelli L, et al. Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes. J Diabetes Complicat. 2017;31:1021–6. https://doi.org/10.1016/j.jdiacomp.2017.01.024.CrossRef

92.

Williams KH, Burns K, Constantino M, Shackel NA, Prakoso E, Wong J, et al. An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. J Diabetes Complicat. 2015;29:1240–7. https://doi.org/10.1016/j.jdiacomp.2015.06.015.CrossRef

93.

Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev. 2018;14:99–114. https://doi.org/10.1038/nrendo.2017.173.CrossRef

94.

Lv WS, Sun RX, Gao YY, Wen JP, Pan RF, Li L, et al. Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes. World J Gastroenterol. 2013;19:3134–42. https://doi.org/10.3748/wjg.v19.i20.3134.CrossRefPubMedPubMedCentral

Title: The Potential Role of Fatty Acids in Treating Diabetic Neuropathy
Author: Mark A. Yorek
Publication date: 01-10-2018
Publisher: Springer US
Published in: Current Diabetes Reports / Issue 10/2018
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-018-1046-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 10/2018

Medicinal Plants with Multiple Effects on Diabetes Mellitus and Its Complications: a Systematic Review

An Overview of Safety Issues on Use of Insulin Pumps and Continuous Glucose Monitoring Systems in the Hospital

Biomarkers in Islet Cell Transplantation for Type 1 Diabetes

Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology

Metabolic Abnormalities in Diabetes and Kidney Disease: Role of Uremic Toxins

Designing the Glucose Telemetry for Hospital Management: From Bedside to the Nursing Station

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials